Loading...
•
Jun 30, 2020
Gilead Sciences Q2 2020 Earnings Report
Gilead Sciences announced results for the second quarter of 2020, with product sales of $5.1 billion and a GAAP loss of $(2.66) per share.
Key Takeaways
Gilead Sciences reported second-quarter revenue of $5.1 billion. GAAP net loss was $(3.3) billion, or $(2.66) per share, which included an acquired in-process research and development (“IPR&D”) charge of $4.5 billion related to Gilead’s acquisition of Forty Seven, Inc. Non-GAAP diluted EPS was $1.11 per share.
Second Quarter Product Sales of $5.1 billion
First Half Product Sales of $10.5 billion
Second Quarter GAAP Loss of $(2.66) per share
Second Quarter Non-GAAP Diluted EPS of $1.11 per share
Gilead Sciences
Gilead Sciences
Gilead Sciences Revenue by Segment
Gilead Sciences Revenue by Geographic Location
Revenue by Segment
HIV Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comEurope Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
Gilead revised its full year 2020 guidance, initially provided on February 4, 2020.
Positive Outlook
- Product Sales of $23 billion to $25 billion
- Non-GAAP Product Gross Margin 86% - 87%
- R&D Expenses Mid-teens percentage growth
- SG&A Expenses High-single digit percentage growth
- Operating Income of $10.7 billion - $13.0 billion